Table 2.

Multivariable logistic regression of PSA level and biopsy grade group predicting adverse pathology at radical prostatectomy.

	Multivariable odds ratio	95% Confidence interval	p
Age, year
50–59 vs. <50	1.35	1.15–1.60	<0.001
60–69 vs. <50	1.74	1.49–2.06	<0.001
70–79 vs. <50	2.35	1.96–2.82	<0.001
Race/ethnicity
Black vs. White	1.00	0.91–1.10	0.98
Others/unknown vs. White	1.24	1.09–1.40	0.001
Clinical T stage (T2 vs. T1)	1.03	0.96–1.11	0.34
Year of diagnosis
2011 vs. 2010	0.92	0.84–1.02	0.104
2012 vs. 2010	0.99	0.90–1.10	0.898
2013 vs. 2010	0.99	0.88–1.10	0.791
2014 vs. 2010	1.10	0.98–1.23	0.099
2015 vs. 2010	1.17	1.05–1.31	0.005
% Positive cores	1.02	1.01–1.02	<0.001
PSA, ng/mL (10–20 vs. <10)	1.87	1.71–2.05	<0.001
Biopsy Grade Group (2 vs. 1)	2.56	2.40–2.73	<0.001

PSA prostate-specific antigen.